此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估从分化 20 (CD20) 抗簇治疗过渡到 Ublituximab 时疗效维持的研究 (ENHANCE)

2026年10月22日 更新者:TG Therapeutics, Inc.

从抗 CD20 治疗过渡到 Ublituximab 时评估疗效的维持

The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.

研究概览

研究类型

介入性

注册 (估计的)

800

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Bydgoszcz、波兰、85-796
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Katowice、波兰、40-555
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Kielce、波兰、25-726
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Krakow、波兰、31-826
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Lodz、波兰、90-324
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Olsztyn、波兰、10-561
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Poznan、波兰、61-583
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Warsaw、波兰、04-141
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Zabrze、波兰
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Żory、波兰、44-240
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Alabama
      • Birmingham、Alabama、美国、35209
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Cullman、Alabama、美国、35058
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • California
      • Orange、California、美国、92697
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Colorado
      • Fort Collins、Colorado、美国、80528
        • 招聘中
        • TG Investigational Site
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20007
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Florida
      • Tampa、Florida、美国、33612
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Georgia
      • Atlanta、Georgia、美国、30309
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Atlanta、Georgia、美国、30322
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Savannah、Georgia、美国、31406
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Illinois
      • Chicago、Illinois、美国、60612
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Indiana
      • Indianapolis、Indiana、美国、46256
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Iowa
      • Iowa City、Iowa、美国、52242
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Kansas
      • Overland Park、Kansas、美国、66212
        • 完全的
        • TG Therapeutics Investigational Trial Site
      • Overland Park、Kansas、美国、66205
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Maryland
      • Lutherville、Maryland、美国、21093
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Massachusetts
      • Boston、Massachusetts、美国、70809
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Boston、Massachusetts、美国、00002
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Foxborough、Massachusetts、美国、02035
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • North Worcester、Massachusetts、美国、01655
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Wellesley、Massachusetts、美国、02481
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Michigan
      • Farmington、Michigan、美国、48334
        • 招聘中
        • TG Investigational Site
    • Minnesota
      • Golden Valley、Minnesota、美国、55422
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Plymouth、Minnesota、美国、55446
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Missouri
      • St Louis、Missouri、美国、63131
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • New York
      • New York、New York、美国、10025
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • New York、New York、美国、11021
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • North Carolina
      • Charlotte、North Carolina、美国、28204
        • 招聘中
        • TG Therapeutics Investigational Trial SiteCharlotte
      • Raleigh、North Carolina、美国、27607
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Ohio
      • Cincinnati、Ohio、美国、45212
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Cleveland、Ohio、美国、44195
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Dayton、Ohio、美国、45417
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73104
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • South Carolina
      • Greenville、South Carolina、美国、29605
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Tennessee
      • Knoxville、Tennessee、美国、37922
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Texas
      • Houston、Texas、美国、77030
        • 完全的
        • TG Therapeutics Investigational Trial Site
    • Utah
      • Salt Lake City、Utah、美国、84103
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Virginia
      • Vienna、Virginia、美国、22182
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Washington
      • Kirkland、Washington、美国、98034
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Seattle、Washington、美国、98109
        • 招聘中
        • TG Therapeutics Investigational Trial Site
      • Spokane、Washington、美国、99208
        • 招聘中
        • TG Therapeutics Investigational Trial Site
    • Wisconsin
      • Milwaukee、Wisconsin、美国、53226
        • 招聘中
        • TG Therapeutics Investigational Trial Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Diagnosis of RMS (2017 Revised McDonald criteria).

  • Participants must meet one of the following prior treatment definitions:

    1. Participants naïve to treatment.
    2. Participants previously treated with a disease modifying therapy (DMT) who have discontinued treatment prior to consent and meet the washout requirements.
  • Expanded Disability Status Scale (EDSS) score ≤ 5.5 at screening.

  • Neurologically stable for > 30 days prior to first dose of ublituximab.

  • Female participants of childbearing potential must consent to use a medically acceptable method of contraception from consent, throughout the study period, and for 6 months after the last dose of ublituximab.

  • Part C: participants currently treated with an anti-CD20 agent for at least 6 months and meet the washout requirements prior to W1D1.

  • Part C: Discontinuation of current anti-CD20 must be due to suboptimal experience

Exclusion Criteria:

  • History of any serious 3 Infusion Related Reaction (IRR) on prior anti-CD20 therapy.
  • Primary-progressive multiple sclerosis (PPMS) or inactive Secondary Progressive MS (SPMS).
  • Active chronic (or stable but treated with immune therapy) disease of the immune system other than MS (e.g., rheumatoid arthritis, scleroderma, Sjögren's syndrome, Crohn's disease, ulcerative colitis, etc.) or immunodeficiency syndrome (hereditary immune deficiency, drug-induced immune deficiency, etc.).
  • Current evidence or known history of clinically significant infection, including: chronic, recurrent, or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment such as, but not limited to chronic urinary tract infection, chronic pulmonary infection with bronchiectasis, tuberculosis, or active hepatitis C virus (HCV).
  • Previous serious opportunistic or atypical infection.
  • Evidence of chronic active or history of hepatitis B virus (HBV) infection as evidenced by a detectable hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody (HBcAb), or chronic hepatitis C infection. Participants with positive hepatitis C virus antibody (HCV Ab) are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).
  • History or evidence (clinical, radiological, or biomarker) of suspected or confirmed progressive multifocal leukoencephalopathy (PML).
  • Receipt of any live or live-attenuated vaccines (including vaccines for varicella-zoster virus or measles) within 4 weeks prior to first study drug administration.
  • Participants requiring treatment with intravenous immune globulin (IVIG) for decreased immunoglobulins within the 12 months prior to W1D1.
  • Any active malignancies other than adequately treated basal, squamous cell or in situ carcinoma.
  • Participants who have ever received ublituximab, alemtuzumab, cyclophosphamide, mitoxantrone, cladribine, or daclizumab (including for non-MS indications).

Note: Other Inclusion/Exclusion criteria may apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Part A: Ublituximab

Participants will receive a modified regimen of ublituximab including infusions on Day 1 of Week 1 (W1D1), Day 15, if applicable, and ublituximab 450 milligrams (mg) infusion at Week 24.

With Protocol Version 6.0, enrollment in Part A was closed.

Administered as an intravenous (IV) infusion.

其他名称:
  • TG-1101
  • 宝马
实验性的:Part B: Ublituximab /Placebo (Treatment Arm A)

Participants will receive 600 mg of ublituximab on W1D1 followed by a placebo infusion on Day 15 and 450 mg ublituximab infusion at Week 24.

With Protocol Version 7.0, enrollment in Part B will be closed.

IV infusion

Administered as an intravenous (IV) infusion.

其他名称:
  • TG-1101
  • 宝马
实验性的:Part B: Ublituximab (Treatment Arm B)

Participants will receive 150 mg of ublituximab on W1D1 followed by 450 mg on Day 15 and at Week 24.

With Protocol Version 7.0, enrollment in Part B will be closed.

Administered as an intravenous (IV) infusion.

其他名称:
  • TG-1101
  • 宝马
实验性的:Part C: Ublituximab (Treatment Arm C)

Participants will receive 150 mg of ublituximab on W1D1, followed by 450 mg on Day 15 and at Week 24.

Administered as an intravenous (IV) infusion.

其他名称:
  • TG-1101
  • 宝马

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Part B:ublituximab 治疗前 16 周曲线下面积(AUC0-W16)
大体时间:给药前及至第16周的多个时间点
给药前及至第16周的多个时间点
Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48
大体时间:Baseline up to Week 48

The Gd-enhancing T1 lesions will be evaluated using magnetic resonance imaging (MRI) technique.

Baseline up to Week 48

次要结果测量

结果测量
措施说明
大体时间
Parts A: Percentage of Participants Free of T1 Gd-Enhancing Lesions
大体时间:Week 48

The Gd-enhancing T1 lesions will be evaluated using MRI technique.

Week 48
Parts A and B: Percentage of Participants Experiencing Infusion Related Reactions (IRRs)
大体时间:Up to Week 48

IRRs are defined as infusion related adverse events (AEs) that occur within one day of an infusion and resolve within 7 days. IRRs will be reported by investigator.

Up to Week 48
Parts A: Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scores
大体时间:Part A: Baseline, Week 24 and Week 48

The TSQM-9 is a 9-item questionnaire with 3 domains: Satisfaction, convenience, and effectiveness.

Part A: Baseline, Week 24 and Week 48

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年6月13日

初级完成 (估计的)

2027年1月21日

研究完成 (估计的)

2027年1月21日

研究注册日期

首次提交

2023年5月18日

首先提交符合 QC 标准的

2023年5月18日

首次发布 (实际的)

2023年5月26日

研究记录更新

最后更新发布 (实际的)

2026年10月23日

上次提交的符合 QC 标准的更新

2026年10月22日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • TG1101-RMS401
  • 2024-519284-18-00 (其他标识符:EU CT Number)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅